STAT3 and urinary bladder carcinoma: Furthermore, HME was proved as a blocker for STAT3 activation, evidenced by the findings that HME inhibits both constitutive and IL-6-induced activation of STAT3, and STAT3 blockage is needed for HME to suppress the viability and clonogenicity of bladder cancer cells (Figure 3).